.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Army
Cipla
Citi
Mallinckrodt
QuintilesIMS
Merck
Teva
McKesson
Baxter

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,703,063

« Back to Dashboard

Summary for Patent: 4,703,063

Title: Sulfamoyl substituted phenethylamine derivatives and process of producing them
Abstract:Novel sulfamoyl-substituted phenethylamine derivatives which exhibit .alpha.-adrenergic blocking action and are useful as an antihypertensive agent and an agent for the treatment of congestive heart failure.
Inventor(s): Imai; Kazuo (Saitama, JP), Niigata; Kunihiro (Saitama, JP), Fujikura; Takashi (Saitama, JP), Hashimoto; Shinichi (Chiba, JP), Takenaka; Toichi (Tokyo, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:06/756,790
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,703,063

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan55-14382Feb 08, 1980

International Patent Family for Patent: 4,703,063

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico9203592► Subscribe
Netherlands950014► Subscribe
Germany19675042► Subscribe
European Patent Office0034432► SubscribeSPC/GB96/017: EXPIREUnited Kingdom► Subscribe
European Patent Office0034432► Subscribe96C0048Belgium► Subscribe
Spain499224► Subscribe
Spain8201966► Subscribe
Greece73827► Subscribe
Ireland810236► Subscribe
Ireland50862► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Deloitte
Cantor Fitzgerald
Harvard Business School
AstraZeneca
Argus Health
Chubb
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot